1. Hutchison I. Improving the prognosis of oral squamous cell carcinoma in 2013. Br Dent J 2013; 215(9):441.
2. Raj LSM, Boaz K, Natarajan S. Prognostic Significance of Lymph Node Pattern in Oral Squamous Cell Carcinoma (OSCC). J Clin Diagn Res 2014; 8(1):232–5.
3. Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol 2014; 48(1):1–10.
4. Verma R, Hansch H. Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q) SARs. Bioorg and Med Chem 2005;15:2223–68.
5. Marchenko G, Ratnikov B, Rozanov D, Godzik A, Deryugina E, Strongin A. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001; 356: 705–18.
6. Oliveira LR, Castilho-Fernandes A, Oliveira-Costa JP, Soares FA, Zucoloto S, Silva AR. CD44+/CD133+ immunophenotype and matrix metalloproteinase-9: Influence on prognosis in early-stage oral squamous cell carcinoma. Head Neck 2014;36(12):1718-26.
7. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger D, Wong DW, Schmidt BL. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004; 10(19):6460–5.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Review 2002; (2):161–74.
9. Mäkinen LK, Häyry V, Hagström J, Sorsa T, Santos FP, Santti HK, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-25 in oral tongue squamous cell carcinoma. Head Neck. 2013; 36(12): 1783-88. Nov 1. doi: 10.1002/hed.23539. [Epub ahead of print].
10. Lee HJ, Kim JW. Immunohistochemical study on the expression of matrix metalloproteinase 2 and high-risk human papilloma virus in the malignant progression of papillomas. J Korean Assoc Oral Maxillofac Surg 2013; 39(5):224–30.
11. de Vicente JC, Fresno MF, Villalain L. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 2005; 41(3):283–93.
12. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent 2012; 4(5):e297–e301.
13. Tamamura R, Nagatsuka H, Siar CH, Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem 2012 11. [Epub ahead of print]
14. Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114(2):240–50.
15. Katayama A, Bandoh N, Kishibe K. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10(2):634–40.
16. Fang J,Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G.Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci 2000; 97(8):3884–9.